This is a study sponsored by UCB (a pharmaceutical company) for their new potential medication, UCB0022. This drug works by working on the target sites in the brain (dopamine receptors) which ultimately increase the dopamine effects in the brain, then reduce patients symptoms. The study is a 18 days stay in a research centre (HMR Parks Royal) where participants are given the drug with doctors and nurses taking care of them. They would have a 3 hour formal screening visit at the site before the study, then after the 18 days of admission, they would need to attend two outpatient follow-up. For finishing the study, they’ll get £3,900 (if additional visits are needed, they will be paid for accordingly to them). A full information sheet can be sent if wishing to know more and have interest in the study.
